Concept paper for the revision of the guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal Management (EMA/522332/2021)
Highlights - 6th EMA-AESGP bilateral meeting
Medicinal products for human use: monthly figures - January 2026
Human medicines European public assessment report (EPAR): Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris, emtricitabine,rilpivirine,tenofovir alafenamide, Date of authorisation: 19/08/2025, Status: Authorised
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9 - 12 February 2026
EMA recommends withdrawal of marketing authorisations for levamisole medicines
Medicine shortage communication (MSC): Natpar (parathyroid hormone) (25, 50, 75 and 100 micrograms/dose powder and solvent for solution for injection)
Clinical investigation of medicinal products in the treatment of Myasthenia Gravis
Concept paper on the need of a guideline on clinical investigation of medicinal products in the treatment of Myasthenia Gravis
Review of the stepwise paediatric investigation plan (sPIP) pilot: Outcomes and future perspectives